In the final episode, 'Access, Coverage, and Final Reflections on Managing Alzheimer's Disease Agitation,' the panelists explored the following critical questions: How has insurance coverage been with the Food and Drug Administration (FDA)-approved therapies for Alzheimer's disease agitation? What are best practices in working with insurance providers to get coverage for patients?
In 'Choosing Between Approved Therapies: Differentiation, Sequencing, and Black Box Warning Navigation in Alzheimer's Disease Agitation,' the expert neurologists examined the following critical questions: In your practice, how are you differentiating antipsychotic therapies from dextromethorphan-bupropion for patients with Alzheimer's disease agitation? With the introduction of 2 Food and Drug Administration (FDA)-approved therapies in the last few years, how are you sequencing treatments in patients with Alzheimer's disease agitation? How are you navigating black box warnings with certain therapies?
In this episode, 'Comparing the Two Approved Therapies: Dextromethorphan-Bupropion and Brexpiprazole in Alzheimer's Disease Agitation,' the expert neurologists explored the following question: What were the key safety and efficacy results that led to its approval and how do they compare with brexpiprazole's?
In 'Brexpiprazole and Dextromethorphan-Buproprion: Mechanisms of Action and Key Clinical Trial Data for Approved Alzheimer's Disease Agitation Therapies,' the expert neurologists examined the following critical questions: Brexpiprazole was approved by the Food and Drug Administration (FDA) in 2023 and dextromethorphan/buproprion in 2026 for the treatment of Alzheimer's disease agitation. What are the mechanisms of action of these therapies? What were the key safety and efficacy results seen in the clinical trials?
In this episode, 'Traditional Pharmacologic Therapies for Alzheimer's Disease Agitation: Mechanisms, Evidence, and Adverse Events,' the expert neurologists explored the following questions: What are the traditional therapies such as antipsychotics used in the management of patients with Alzheimer's disease agitation and their respective mechanisms of action? What has the data demonstrated with these therapies? What are the adverse events seen with these therapies? When are you utilizing dose reductions with these therapies?
In 'Non-Pharmacologic Approaches to Alzheimer's Disease Agitation: Interventions, Best Practices, and Case Examples,' the expert neurologists examined the following critical questions: Before we get into the medications used to treat Alzheimer's disease agitation, what are the non-pharmacologic options and their respective roles? What are best practices for educating patients and caregivers on these and some case examples?
Alireza Atri introduces mild behavioral impairment as an early-emerging framework for behavioral changes preceding formal dementia diagnosis.
Kavita Nair leads the discussion on defining Alzheimer's disease agitation.
In this episode, 'Closing the Recognition Gap: Underdiagnosis, Patient Education, and Treatment Goals in Alzheimer's Disease Agitation,' the expert neurologists explored the following questions: Do you believe that Alzheimer's disease agitation is currently underdiagnosed? How are you educating patients and families? What are the treatment goals for patients with Alzheimer's disease agitation?
In 'The Burden of Alzheimer's Disease Agitation: Impact on Patients, Caregivers, and Quality of Life,' the expert neurologists examined the following critical questions: What is the impact that Alzheimer's disease agitation has on patients, as well as their caregivers, and what is the necessary education? How can it impact quality of life and impact families?
Leda Mannent, MD, global project head, Immunology and Inflammation, Sanofi, discusses efficacy outcomes in patients with asthma who received rilzabrutinib.
Susan Spratt, MD, senior medical director, Duke Population Health Management Office, breaks down the the prevalence of diabetes in the United States and discusses current diabetes initiatives at Duke Health.
This London-based charity intervenes in the short term when its clients come up against roadblocks that prevent ready access to good levels of nutrition, whether that crisis is nutritional, physical/mental health, housing, or financial related.
With empagliflozin, we now have evidence that another treatment for patients with heart failure with preserved ejection fraction (HFpEF) is possible, said Stefan Anker, MD, PhD, FESC, professor of cardiology, Department of Cardiology, Charité Campus Virchow Clinic, Berlin, Germany, and principal investigator of the EMPEROR-Preserved study.
Clinicians are finding that there really is no basis to recommend probiotics for patients with Clostridioides difficile infection, that instead they may cause harm, said Colleen R. Kelly, MD, FACG, gastroenterologist and associate professor of medicine at The Warren Alpert Medical School of Brown University.
Differentiated service delivery models can be employed to incorporate other chronic disease needs for patients with HIV, emphasized Helen Bygrave, MD, Médecins Sans Frontières (Doctors Without Borders).
Patients who undergo transplant face an increased risk of skin cancer because of their immunosuppressed status, explained Christine Ko, MD, professor of dermatology and pathology at Yale University.
Having one of the lowest adult HIV prevalence rates in the world is a significant public health success story, explained Jason Myers, PhD, CEO of the New Zealand AIDS Foundation.
Treatment for heart failure with preserved ejection fraction (HFpEF) may soon resemble that for heart failure with reduced ejection fraction (HFrEF), noted Javed Butler, MD, MPH, MBA, of the University of Mississippi.
Being a full-service dermatology practice helps make patients' lives easier when they have skin cancer, explained Todd Schlesinger, MD, FAAD, director, Dermatology and Laser Center of Charleston and Clinical Research Center of the Carolinas.
Sodium-glucose co-transporter 2 (SGLT2) inhibitors have been shown to both lower blood pressure and promote weight loss, and they act rather subtly, stated Rudolf de Boer, MD, PhD, clinical cardiologist and professor of translational cardiology, University Medical Center Groningen, the Netherlands.
There was a reduction in both the need for dialysis and progression to end-stage renal disease; finerenone was really well tolerated, stated Bertram Pitt, MD, professor of medicine emeritus, University of Michigan School of Medicine.
With finerenone being a targeted therapy, data show there may be an additive cardiorenal benefit when it is coadministered with a sodium glucose co-transporter 2 inhibitor, noted Dipti Itchhaporia, MD, FACC, FAHA, FESC, president of the American College of Cardiology.
Whatever your theory of heart failure with preserved ejection fraction, sodium glucose co-transporter 2 (SGLT2) inhibitors seem to be attacking every one, noted Javed Butler, MD, MPH, MBA, University of Mississippi.
Sodium glucose co-transporter 2 (SGLT2) inhibitor use in patients with heart failure with preserved ejection fraction (HFpEF) has generated great enthusiasm, noted Rudolf de Boer, MD, PhD, clinical cardiologist and professor of translational cardiology, University Medical Center Groningen, the Netherlands.
The composite end point of cardiovascular death and heart failure hospitalization was reduced by 21%, which is highly statistically significant and clinically meaningful, noted Stefan Anker, MD, PhD, FESC, principal investigator of EMPEROR-Preserved.
There are incredible data for sodium-glucose co-transporter 2 (SGLT2) inhibitors, and this is a great class of medicines that is vastly underutilized, stated Deepak L. Bhatt, MD, MPH, executive director of interventional cardiovascular programs at Brigham and Women’s Hospital Heart & Vascular Center and professor of medicine at Harvard Medical School.
There will be new ESC heart failure guidelines and presentation of data from EMPEROR-Preserved and EMPEROR-Pooled, noted Rudolf de Boer, MD, PhD, of University Medical Center Groningen, the Netherlands.
Krajowe Centrum ds AIDS (National AIDS Center) in Warsaw, Poland, was founded in 1993 as part of the country’s Ministry of Health. Its chief area of advocacy and outreach is access to antiretroviral treatment, in addition to new areas of focus that include prevention of sexually transmitted infections and hepatitis C virus.
Actinic keratosis outcomes can be affected by several variables, and these lesions need to be treated to minimize progression risk, noted Todd Schlesinger, MD, FAAD, director, Dermatology and Laser Center of Charleston and Clinical Research Center of the Carolinas.
